Equities research analysts predict that Radius Health Inc (NASDAQ:RDUS) will post sales of $25.47 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Radius Health’s earnings. The lowest sales estimate is $23.41 million and the highest is $27.00 million. Radius Health posted sales of $13.47 million during the same quarter last year, which would indicate a positive year over year growth rate of 89.1%. The firm is expected to report its next quarterly earnings report before the market opens on Thursday, November 1st.
On average, analysts expect that Radius Health will report full year sales of $96.24 million for the current fiscal year, with estimates ranging from $88.08 million to $105.79 million. For the next year, analysts forecast that the business will report sales of $169.69 million, with estimates ranging from $150.47 million to $188.61 million. Zacks’ sales averages are an average based on a survey of analysts that follow Radius Health.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.35) by $0.36. Radius Health had a negative return on equity of 110.71% and a negative net margin of 444.70%. The firm had revenue of $22.63 million for the quarter, compared to analyst estimates of $20.84 million.
Several equities research analysts have recently weighed in on the company. BidaskClub lowered Radius Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $25.00 price objective on shares of Radius Health in a research note on Tuesday, August 7th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Bank of America lowered their price objective on Radius Health from $51.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, July 25th. Finally, JPMorgan Chase & Co. lowered their price objective on Radius Health from $60.00 to $59.00 and set a “$28.40” rating on the stock in a research note on Monday, July 23rd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Radius Health presently has a consensus rating of “Hold” and an average target price of $49.14.
RDUS traded up $0.68 on Friday, hitting $19.21. 493,037 shares of the stock traded hands, compared to its average volume of 836,427. Radius Health has a 52 week low of $16.71 and a 52 week high of $41.16. The company has a quick ratio of 5.26, a current ratio of 5.39 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $809.48 million, a price-to-earnings ratio of -3.31 and a beta of 0.95.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 169,363 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were acquired at an average cost of $20.83 per share, for a total transaction of $3,527,831.29. Following the transaction, the insider now directly owns 6,460,913 shares in the company, valued at $134,580,817.79. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, July 27th. The shares were acquired at an average price of $24.81 per share, for a total transaction of $1,240,500.00. Following the completion of the transaction, the insider now owns 6,300,913 shares in the company, valued at $156,325,651.53. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 389,363 shares of company stock worth $8,675,131. Corporate insiders own 3.42% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RDUS. Swiss National Bank grew its position in Radius Health by 5.6% during the 1st quarter. Swiss National Bank now owns 57,000 shares of the biopharmaceutical company’s stock worth $2,049,000 after acquiring an additional 3,000 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Radius Health by 4.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 191,510 shares of the biopharmaceutical company’s stock worth $6,883,000 after acquiring an additional 8,935 shares during the last quarter. Aperio Group LLC bought a new stake in Radius Health during the 1st quarter worth approximately $231,000. OppenheimerFunds Inc. bought a new stake in Radius Health during the 1st quarter worth approximately $29,903,000. Finally, Farallon Capital Management LLC grew its position in Radius Health by 3.8% during the 1st quarter. Farallon Capital Management LLC now owns 4,086,300 shares of the biopharmaceutical company’s stock worth $146,862,000 after acquiring an additional 150,000 shares during the last quarter.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
See Also: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.